Overview

SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma

Status:
Recruiting

Trial end date:
2022-06-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to observe the efficacy and safety of immume checkpoint inhibitor PD-1 SHR1210 combined with Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of locally advanced resectable gastric and gastroesophageal junction adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Henan Cancer Hospital

Treatments:

Capecitabine
Oxaliplatin
Trastuzumab